Recombinant human activated protein C for the postexposure treatment of Ebola hemorrhagic fever
- PMID:17940975
- DOI: 10.1086/520598
Recombinant human activated protein C for the postexposure treatment of Ebola hemorrhagic fever
Abstract
Background: Infection of primates with Zaire ebolavirus (ZEBOV) leads to hypotension, coagulation disorders, and an impaired immune response and, in many ways, resembles severe sepsis. Rapid decreases in plasma levels of protein C are a prominent feature of severe sepsis and ZEBOV hemorrhagic fever (ZHF). Currently, recombinant human activated protein C (rhAPC [Xigris; Eli Lilly]) is licensed for treating human patients with severe sepsis who are at high risk of death. The aim of this study was to test the efficacy of rhAPC as a potential treatment for ZHF.
Methods: Fourteen rhesus macaques were challenged with a uniformly lethal dose of ZEBOV; 11 of these monkeys were treated by intravenous infusion with rhAPC beginning 30-60 min after challenge and continuing for 7 days. Three control monkeys received sterile saline in parallel.
Results: All 3 control monkeys died on day 8, whereas 2 of the 11 rhAPC-treated monkeys survived. The mean time to death for the rhAPC-treated monkeys that did not survive ZEBOV challenge was 12.6 days. The difference in survival was significant when the rhAPC-treated monkeys were compared with historical controls.
Conclusions: The experimental findings provide evidence that ZHF and severe sepsis share underlying mechanisms and may respond to the same therapies.
Similar articles
- The use of recombinant human activated protein C (rhAPC) in the treatment of severe sepsis in immunosuppressed patients in the course of hematological diseases.Kunsdorf-Wnuk A, Marzec-Lewenstein E, Arct-Danielak D, Musioł E, Bohatyrewicz R, Becht R.Kunsdorf-Wnuk A, et al.Med Sci Monit. 2005 Aug;11(8):CS49-55. Epub 2005 Jul 25.Med Sci Monit. 2005.PMID:16049385
- Assessment of a vesicular stomatitis virus-based vaccine by use of the mouse model of Ebola virus hemorrhagic fever.Jones SM, Stroher U, Fernando L, Qiu X, Alimonti J, Melito P, Bray M, Klenk HD, Feldmann H.Jones SM, et al.J Infect Dis. 2007 Nov 15;196 Suppl 2:S404-12. doi: 10.1086/520591.J Infect Dis. 2007.PMID:17940977
- Treatment of Ebola virus infection with a recombinant inhibitor of factor VIIa/tissue factor: a study in rhesus monkeys.Geisbert TW, Hensley LE, Jahrling PB, Larsen T, Geisbert JB, Paragas J, Young HA, Fredeking TM, Rote WE, Vlasuk GP.Geisbert TW, et al.Lancet. 2003 Dec 13;362(9400):1953-8. doi: 10.1016/S0140-6736(03)15012-X.Lancet. 2003.PMID:14683653
- Current knowledge on lower virulence of Reston Ebola virus (in French: Connaissances actuelles sur la moindre virulence du virus Ebola Reston).Morikawa S, Saijo M, Kurane I.Morikawa S, et al.Comp Immunol Microbiol Infect Dis. 2007 Sep;30(5-6):391-8. doi: 10.1016/j.cimid.2007.05.005. Epub 2007 Jul 3.Comp Immunol Microbiol Infect Dis. 2007.PMID:17610952Review.
- Activated protein C and the ovarian hyperstimulation syndrome: possible therapeutic implications.Hitkari JA, Rowe TP, von Dadelszen P.Hitkari JA, et al.Med Hypotheses. 2006;66(5):929-33. doi: 10.1016/j.mehy.2005.08.058. Epub 2006 Jan 24.Med Hypotheses. 2006.PMID:16434147Review.
Cited by
- A Syrian golden hamster model recapitulating ebola hemorrhagic fever.Ebihara H, Zivcec M, Gardner D, Falzarano D, LaCasse R, Rosenke R, Long D, Haddock E, Fischer E, Kawaoka Y, Feldmann H.Ebihara H, et al.J Infect Dis. 2013 Jan 15;207(2):306-18. doi: 10.1093/infdis/jis626. Epub 2012 Oct 8.J Infect Dis. 2013.PMID:23045629Free PMC article.
- Sustained protection against Ebola virus infection following treatment of infected nonhuman primates with ZMAb.Qiu X, Audet J, Wong G, Fernando L, Bello A, Pillet S, Alimonti JB, Kobinger GP.Qiu X, et al.Sci Rep. 2013 Nov 28;3:3365. doi: 10.1038/srep03365.Sci Rep. 2013.PMID:24284388Free PMC article.
- Ebola Viral Disease in West Africa: A Threat to Global Health, Economy and Political Stability.Omoleke SA, Mohammed I, Saidu Y.Omoleke SA, et al.J Public Health Afr. 2016 Aug 17;7(1):534. doi: 10.4081/jphia.2016.534. eCollection 2016 Aug 17.J Public Health Afr. 2016.PMID:28299152Free PMC article.
- In vivo Ebola virus infection leads to a strong innate response in circulating immune cells.Caballero IS, Honko AN, Gire SK, Winnicki SM, Melé M, Gerhardinger C, Lin AE, Rinn JL, Sabeti PC, Hensley LE, Connor JH.Caballero IS, et al.BMC Genomics. 2016 Sep 5;17(1):707. doi: 10.1186/s12864-016-3060-0.BMC Genomics. 2016.PMID:27595844Free PMC article.
- Recombinant vesicular stomatitis virus vector mediates postexposure protection against Sudan Ebola hemorrhagic fever in nonhuman primates.Geisbert TW, Daddario-DiCaprio KM, Williams KJ, Geisbert JB, Leung A, Feldmann F, Hensley LE, Feldmann H, Jones SM.Geisbert TW, et al.J Virol. 2008 Jun;82(11):5664-8. doi: 10.1128/JVI.00456-08. Epub 2008 Apr 2.J Virol. 2008.PMID:18385248Free PMC article.
Publication types
MeSH terms
Substances
Related information
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical